Get the Stockscreener App
167.53
2.25%
-3.86
After Hours:
167.01
-0.52
-0.31%
Insulet Corp stock is traded at $167.53, with a volume of 1.47M.
It is down -2.25% in the last 24 hours and down -18.00% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
See More
Previous Close:
$171.39
Open:
$170.86
24h Volume:
1.47M
Relative Volume:
1.37
Market Cap:
$11.60B
Revenue:
$2.71B
Net Income/Loss:
$247.10M
P/E Ratio:
47.85
EPS:
3.5008
Net Cash Flow:
$349.90M
1W Performance:
-8.39%
1M Performance:
-18.00%
6M Performance:
-46.72%
1Y Performance:
-35.26%
1-Day Range:
$166.74
$170.98
1-Week Range:
$158.35
$182.91
52-Week Range:
$158.35
$354.88
Insulet Corp Stock (PODD) Company Profile
Name
Insulet Corp
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corp
|
167.53 | 11.87B | 2.71B | 247.10M | 349.90M | 3.5008 |
ABT
Abbott Laboratories
|
87.17 | 152.48B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 111.40B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 100.53B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 84.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 48.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
Insulet Corp Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Apr-07-26 | Downgrade | Citigroup | Buy → Neutral |
| Jan-27-26 | Resumed | TD Cowen | Hold |
| Jan-12-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-16-25 | Initiated | Evercore ISI | Outperform |
| Nov-19-25 | Upgrade | UBS | Neutral → Buy |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Resumed | Oppenheimer | Outperform |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| May-13-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-29-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-06-25 | Initiated | RBC Capital Mkts | Outperform |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corp Stock (PODD) Latest News
Insulet in the spotlight: Can earnings calm investor nerves? By Investing.com - Investing.com South Africa
8.9 million insulin pods returned as Insulet expands recycling - Stock Titan
Insulet Corp. stock underperforms Monday when compared to competitors - MarketWatch
Insulet (PODD) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance
Insulet (PODD) Upgraded to Buy: Here's Why - Yahoo Finance
Insulet enrolls first patient in closed-loop insulin study - Investing.com
Insulet begins study of insulin system that removes mealtime dosing - Stock Titan
Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes - ChartMill
Why Insulet (PODD) Is Down 7.7% After FDA Class I Omnipod 5 Recall ExpansionAnd What's Next - Yahoo Finance
Insulet Corporation (NASDAQ:PODD) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Insulet Corp. Experiences Revision in Stock Evaluation Amidst Elevated Valuation Metrics - Markets Mojo
Comerica Bank Sells 17,712 Shares of Insulet Corporation $PODD - MarketBeat
Insulet Corp. stock underperforms Wednesday when compared to competitors - MSN
Insulet Corporation $PODD Holdings Lifted by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
Insulet Corp. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
MSN Money - MSN
INSULET CORP (NASDAQ:PODD): A Textbook GARP Candidate for Affordable Growth Investors - ChartMill
Rothschild & Co Redburn Downgrades Insulet Corporation (PODD), Cites “Eroding” Product Moats and Distribution - Insider Monkey
Insulet Corp. Stock Plummets to New 52-Week Low of $158.42 - Markets Mojo
Insulet Corp. Stock Hits Day Low of $158.42 Amid Price Pressure - Markets Mojo
This Insulet analyst is no longer bullish; here are top 4 downgrades for Friday - MSN
Earnings Preview: Insulet to Report Financial Results Pre-market on May 06 - Moomoo
Is Insulet (PODD) Turning Device Corrections Into a Test of Its Innovation-Driven Risk Strategy? - simplywall.st
Insulet Corp (PODD) Shares Surge 7.6% -- What GF Score of 85 Tells Investors - GuruFocus
Insulet Corp. stock underperforms Thursday when compared to competitors despite daily gains - MSN
Insulet Corporation (PODD) Updates on Medical Device Correction and FDA Communication - GuruFocus
Recalled Omnipod 5 Injuries Skyrocket, Prompting Removal of Insulin Pump Pods - AboutLawsuits.com
Vanguard discloses 5.28M-share stake in Insulet (NASDAQ: PODD) - Stock Titan
Insulet Corporation stock hits 52-week low at 177.81 USD By Investing.com - Investing.com Canada
Vanguard Group Inc. Sells 94,728 Shares of Insulet Corporation $PODD - MarketBeat
A Look at Insulet Corp (PODD) After 12.5% Decline -- GF Value $3 - GuruFocus
Insulet Drops 8.8% Amid Sector-Wide Selling - AlphaStreet
Insulet Clarifies FDA Injury Reports on Device Correction - TipRanks
Insulet (PODD) explains 29 serious events vs 476 FDA device reports - Stock Titan
Insulet (NASDAQ:PODD) Shares Down 8.9%Here's What Happened - MarketBeat
FDA Flags High-Risk Recall Of Insulet's Omnipod 5 Pods Over Insulin Delivery Concerns - Benzinga
Insulet (PODD) Issues Safety Advisory on Affected Pod Lots - GuruFocus
Insulet Down Over 11%, On Pace for Largest Percent Decrease Since May 2020 -- Data Talk - 富途牛牛
Insulet Corp. Stock Plummets to New 52-Week Low of $182.27 - Markets Mojo
Insulet (PODD) Ends April With Strong Analyst Sentiment Amid Strong Earnings Expectations - Insider Monkey
Here's Why You Should Retain PODD Stock in Your Portfolio Now - MSN
Insulet Corporation stock hits 52-week low at 177.81 USD - Investing.com
Joel Isaacson & Co. LLC Increases Stock Holdings in Insulet Corporation $PODD - MarketBeat
Insulet (PODD) to Release Quarterly Earnings on Wednesday - MarketBeat
Insulet’s Omnipod Growth Story Is Strong, But The Stock Is Pricey - Finimize
Insulet Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Insulet (NASDAQ:PODD) Sets New 52-Week LowTime to Sell? - MarketBeat
Insulet to Participate in BofA Securities 2026 Health Care Conference - BioSpace
Insulet Corporation earnings preview: What to expect - MSN
Insulet stock (US45784P1012): Is tubeless insulin delivery strong enough to unlock new upside? - AD HOC NEWS
Diabetes device maker Insulet to webcast May 13 investor talk - Stock Titan
Insulet Corp Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):